Advertisement

Klinischer Nutzen psychoneuroendokrinologischer Untersuchungen

  • F. Holsboer
Conference paper

Zusammenfassung

Lange vor der Entdeckung der Psychopharmaka erhoffte man durch die Erforschung hormoneller Vorgänge Grundlagen für die gesunde psychische Entwicklung zu finden. Der Schweizer Psychiater Manfred Bleuler definierte 1954 die Aufgaben dieses Forschungsgebietes, das er in Anlehnung an Laignel-Lavastine „endokrinologische Psychiatrie“nannte. Er verstand darunter die Lehre von den Zusammenhängen zwischen endokrinologischen und psychischen Krankheitserscheinungen. Besonders hervorzuheben ist, daß Bleuler die Hypothese überprüfen wollte, ob psychopathologi-sche und endokrinologische Auffälligkeiten verschiedene Seiten ein und desselben Lebensvorganges sind, oder ob sie sich gegenseitig beeinflussen. In engem Zusammenhang mit diesen ätiologisch ausgerichteten Fragen stand der Wunsch, die aus der endokrinologisch-psychiatrischen Forschung gewonnenen Erfahrungen klinisch umzusetzen. Man erwartete zu dieser Zeit Kenntnisse darüber zu erlangen, „ob und wie sich die Persönlichkeit und ihre Störungen durch das Endokrinium treffende Behandlungen beeinflussen lassen und umgekehrt“. Die Hypothese, vom Endokrinium aus die Psyche und von der Psyche aus das Endokrinium zu beeinflussen, erweckte große therapeutische Hoffnungen. Man glaubte bald, mit Hilfe von Hormontherapien manisch-depressive Patienten, Schizophrenie, Epilepsie, Neurosen, Psychopathien und andere psychische Erkrankungen heilen zu können. Auch hoffte man, die Reifung des Gesunden lenken und sein Altern verzögern zu können.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. American Psychiatric Association (1980) Diagnostic and Statistic Manual of Mental Disorders (DSM-III), 3rd ed. American Psychiatric Association, Washington DCGoogle Scholar
  2. Angst J, Dobler-Mikola A (1984) The Zurich Study. II. The continuum from normal to pathological depressive mood swings. Eur Arch Psychiat Neurol Sci 234: 21 – 29CrossRefGoogle Scholar
  3. Arana GW, Workman RJ, Baldessarini RJ (1984) Association between low plasma levels of dexamethasone and elevated levels of Cortisol in psychiatric patients given dexamethasone. Amer J Psychiat 141: 1619–1620PubMedGoogle Scholar
  4. Asnis GM, Sachar EJ, Halbreich U, Nathan RS, Ostrow L, Halpern FS (1981) Cortisol secretion and dexamethasone response in depression. Amer J Psychiat 138: 1218 – 1221PubMedGoogle Scholar
  5. Baldessarini R, Finklestein S, Arana GW (1983) The predictive power of diagnostic tests and the effect of prevalence of illness. Arch Psychiat 40: 569 – 573Google Scholar
  6. Bardeleben U v, Holsboer F, Stalla GK, Müller OA (1985) Combined administration of human corticotropin-releasing factor and lysine vasopressin induces Cortisol escape from dexamethasone suppression in healthy subjects. Life Sciences 37:1613 – 1618CrossRefGoogle Scholar
  7. Bech P, Gjerris A, Anderson J (1983) The melancholia scale and the Newcastle scales: itemcombination and inter-observer reliability. Brit J Psychiat 143: 58 – 63PubMedCrossRefGoogle Scholar
  8. Beckmann H, Holzmüller B, Fleckenstein P (1984) Clinical investigations into antidepressive mechanisms. II. Dexamethasone suppression test predicts response to nomifensine or amitriptyline. Acta psychiat scand 70: 342 – 353PubMedCrossRefGoogle Scholar
  9. Berger M, Doerr P, Lund T, Bronisch T, Zerssen D v (1982) Neuroendocrinological and neurophysiological studies in major depressive disorders: Are there biological markers for the endogenous subtype? Biol Psychiat 17: 1217 – 1242PubMedGoogle Scholar
  10. Berger M, Pirke KM, Doerr P, Krieg JC, Zerssen D v (1983) Influence of weight loss on the dexamethasone suppression test. Arch gen Psychiat 40: 585 – 586PubMedCrossRefGoogle Scholar
  11. Berger M, Pirke KM, Doerr P, Krieg JC, Zerssen D v (1984) The limited utility of the dexamethasone supression test for the diagnostic process in psychiatry. Brit J Psychiat 145: 372–382PubMedCrossRefGoogle Scholar
  12. Bleuler M (1954) I. Einleitung: Ziele, Grundlagen und Grenzen. In: Bleuler M (ed) Endokrinologische Psychiatrie. Thieme, Stuttgart, S 1–27Google Scholar
  13. Britton DR, Koob GF, Rivier J, Vale W (1982) Intraventricular corticotropin-releasing factor enhances behavioral effects of novelty. Life Sci 31: 363 – 367PubMedCrossRefGoogle Scholar
  14. Brown WA, Johnston R, Mayfield D (1979) The 24-hour dexamethasone suppression test in a clinical setting: relationship to diagnosis, symptoms and response to treatment. Amer J Psychiat 136:543–547PubMedGoogle Scholar
  15. Brown WA (1980) Dexamethasone suppression test identifies subtypes of depression which respond to different antidepressant. Lancet I: 928 – 929Google Scholar
  16. Cantwell DP, Sturzenberger S, Burroughs J, Salkin B, Green JK (1977) Anorexia nervosa, an affective disorder? Arch gen Psychiat 34: 1037–1093CrossRefGoogle Scholar
  17. Carroll, BJ (to be published) Dexamethasone suppression test: a review of contemporary confusion. J Clin PsychiatGoogle Scholar
  18. Carroll BJ, Schroeder K, Mukhodpadhyay S et al. (1980) Plasma dexamethasone concentrations and Cortisol suppression response in patients with endogenous depression. J Clin Endocrinol Metab 51: 433–437PubMedCrossRefGoogle Scholar
  19. Carroll BJ, Feinberg M, Greden JF et al. (1981) A specific laboratory test for the diagnosis of melancholia. Arch gen Psychiat 38: 15 – 22PubMedCrossRefGoogle Scholar
  20. Checkley SA (1980) Neuroendocrine tests of monoamine function in man: a review of basic theory and its application to the study of depressive illness. Psychol Med 10: 35 – 53PubMedCrossRefGoogle Scholar
  21. Dewan MJ, Pandurangi AK, Boucher ML, Levy BF, Major LF (1982) Abnormal dexamethasone suppression test results in chronic schizophrenic patients. Amer J Psychiat 139:1501–1503PubMedGoogle Scholar
  22. Evans DL, Nemeroff CB (1984) Clinical use of the dexamethasone suppression test in DSM III affective disorders. Arch gen Psychiat, submittedGoogle Scholar
  23. Extein I, Pottash ALC, Gold MS (1981) Relationship to thyrotropin-releasing hormone test and dexamethasone suppression test abnormalities in unipolar depression. Psychiat Res 4:49 – 53CrossRefGoogle Scholar
  24. Extein I, Pottash ALC, Gold MS, Cowdry RW (1982) Using the protirelin test to distinguish mania from schizophrenia. Arch gen Psychiat 39: 77 – 81PubMedCrossRefGoogle Scholar
  25. Galen RS (1983) The predictive value of laboratory diagnoses. Bull Mol Biol Med 8:159–169Google Scholar
  26. Georgotas A, Stokes PE, Krakowski M, Fanelli C, Cooper T (1984) Hypothalamic-pituitary-adrenocortical function in geriatric depression: diagnostic and treatment implications. Biol Psychiat 19:685–693PubMedGoogle Scholar
  27. Gerken A, Holsboer F (1985) Cortisol and corticosterone response after syncorticotropin in relationship to dexamethasone suppressibility of Cortisol. PsychoneuroendocrinolGoogle Scholar
  28. Gerken A, Maier W, Holsboer F (to be published) Weekly monitoring of dexamethasone suppression response in depression: its relationship to change of body weight and psychopathology. Psychoneuroendocrinol 10:261–271Google Scholar
  29. Gold MS, Pottasch ALC, Ryan N, Sweeney DR, Davies RK, Martin DM (1980) TRH-induced TSH response in unipolar bipolar and secondary depressions: possible utility in clinical assessment and differential diagnosis. Psychoneuroendocrinol 5: 144–155CrossRefGoogle Scholar
  30. Greden JF, Gardner R, King D, Grunhaus L, Kronfol Z, Carroll BJ (1983) Dexamethasone suppression tests in antidepressant treatment of melancholia. The process of normalization and test-retest reproducibility. Arch gen Psychiat 40: 493 – 500PubMedCrossRefGoogle Scholar
  31. Heimann H (1979) Klinische und psychopathologische Grundlagen. In: Kisker KP, Meyer JE, Müller C, Strömgren E (eds) Psychiatrie der Gegenwart, Forschung und Praxis, Grundlagen und Methoden der Psychiatrie, Teil 1. Springer, Berlin Heidelberg New York, S 2–42Google Scholar
  32. Holsboer F, Bender W, Benkert O, Klein HE, Schmauss M (1980) Diagnostic value of dexamethasone suppression test in depression. Lancet I: 706CrossRefGoogle Scholar
  33. Holsboer F, Liebl R, Hofschuster E (1982a) Repeated dexamethasone suppression test during depressive illness. Normalization of the test result compared with clinical improvement. J Affect Dis 4: 93–101PubMedCrossRefGoogle Scholar
  34. Holsboer F, Winter K, Doerr HG, Sippell WG (1982b) Dexamethasone suppression test in female patients with endogenous depression: determination of plasma corticosterone, 11-deoxycorticosterone, 11-deoxycortisol, Cortisol and cortisone. Psychoneuroendocrinol 7: 329–338CrossRefGoogle Scholar
  35. Holsboer F, Doerr HG, Sippell WG (1982c) Dexamethasone suppression of 11-deoxycorticosterone, corticosterone, and Cortisol in depressed female patients and normal controls. Acta psychiat scand 66: 18 – 25PubMedCrossRefGoogle Scholar
  36. Holsboer F (1983) Prediction of clinical course by dexamethasone suppression test (DST) response in depressed patients — physiological and clinical construct validity of the DST —. Pharmacopsychiat 16: 186–191CrossRefGoogle Scholar
  37. Holsboer F, Steiger A, Maier W (1983a) Four cases of reversion to abnormal dexamethasone suppression test response as indicator of clinical relapse: a preliminary report. Biol Psychiat 18: 911–916PubMedGoogle Scholar
  38. Holsboer F, Doerr HG, Sippell WG (1983b) Increased sensitivity of the dexamethasone suppression test in depressed female patients based on multisteroid analysis. Psychiat Res 8: 49–57CrossRefGoogle Scholar
  39. Holsboer F, Gerken A, Steiger A, Fass V (1984a) The mean 14.00h— 17.00h plasma Cortisol concentration and its relationship to the 1 mg dexamethasone suppression response in depressives and controls. Acta psychiat scand 69: 383 – 390PubMedCrossRefGoogle Scholar
  40. Holsboer F, Haack D, Gerken A, Vecsei P (1984b) Plasma dexamethasone concentrations and differential glucocorticoid suppression response in depressives and controls. Biol Psychiat 19: 281–291PubMedCrossRefGoogle Scholar
  41. Holsboer F, Philipp M, Gerken A (1984c) Dexamethasone suppression test (DST) and weight loss. Psychiat Res 13: 353–354CrossRefGoogle Scholar
  42. Holsboer F, Müller OA, Doerr HG et al. (1984d) ACTH and multisteroid responses to corticotropin-releasing factor in depressive illness: relationship to multisteroid responses after ACTH stimulation and dexamethasone suppression. Psychoneuroendocrinol 9: 147 – 160CrossRefGoogle Scholar
  43. Holsboer F, Gerken A, Steiger A, Benkert O, Müller OA, Stalla GK (1984e) Corticotropin-releasing factor induced pituitary-adrenal response in depression. Lancet I: 55CrossRefGoogle Scholar
  44. Holsboer F, Bardeleben U v, Gerken A, Stalla GK, Müller OA (1984f) Blunted corticotropin and normal Cortisol response to human corticotropin releasing factor (h —CRF) in depression. New Engl J Med 311: 1127PubMedGoogle Scholar
  45. Holsboer F (1985) Die Entwicklung endokrinologischer Tests in der Depressions-Forschung am Beispiel des Dexamethason-Suppressions-Test. In: Hippius H, Matussek N (Hrsg) Advances in Pharmacotherapy. S Karger AG, Basel (Differentialtherapie der Depression — Möglichkeiten und Grenzen, Vol II, pp 101 – 119)Google Scholar
  46. Holsboer F, Benkert O (1985) Neuroendokrinologische und endokrinologische Forschung bei depressiven Patienten. Nervenarzt 56: 1 – 11PubMedGoogle Scholar
  47. Holsboer F, Gerken A, Bardeleben U v, Grimm W, Stalla GK, Müller OA (1985a) Relationship between pituitary responses to human corticotropin-releasing factor and thyrotropin-releasing hormone in depressives and normal controls. Europ J Pharmacol 110: 153 – 154CrossRefGoogle Scholar
  48. Holsboer F, Wiedemann K, Gerken A, Boll E (to be published) The plasma dexamethasone variable in depression — test retest studies and early biophase kinetics. Psychiat ResGoogle Scholar
  49. Johnson GF, Hunt G, Kerr K, Caterson I (1984) Dexamethasone suppression test (DST) and plasma dexamethasone levels in depressed patients. Psychiat Res 13: 305 – 313CrossRefGoogle Scholar
  50. Kendell RE (1976) The classification of depressions: a review of contemporary confusion. Brit J Psychiat 129: 15–28PubMedCrossRefGoogle Scholar
  51. King D, Dowdy S, Jack R, Gardner R, Edwards P (1982) the dexamethasone suppression test as a predictor of sleep deprivation antidepressant effect. Psychiat Res 7: 93 – 99CrossRefGoogle Scholar
  52. Laakmann G, Benkert O (1978) Neuroendokrinologie und Psychopharmaka. Arzneim Forsch/Drug Res 28: 1277–1280Google Scholar
  53. Labrie F, Giguere V, Proulx L, Lefevre G (1984) Interactions between CRF epinephrine vasopressin and glucocorticoids in the control of ACTH secretion. J Steroid Biochem 20: 153–160PubMedCrossRefGoogle Scholar
  54. Langer G, Resch F, Aschauer H, Keshavan MS, Koinig G, Schönbeck G, Dittrich R (1984) TSH-response patterns to TRH stimulation may indicate therapeutic mechanisms of antidepressant and neuroleptic drugs. Neuropsychobiol 11: 213 – 218CrossRefGoogle Scholar
  55. Loosen PT, Prange AJ jr (1982) Serum thyrotropin response to thyrotropin-releasing hormone in psychiatric patients: a review. Amer J Psychiat 139: 405–416PubMedGoogle Scholar
  56. Matussek N (1978) Neuroendokrinologische Untersuchungen bei depressiven Syndromen. Nervenarzt 49: 569–575PubMedGoogle Scholar
  57. Mezey E, Kiss JZ, Skirboll LR, Goldstein M, Axelrod J (1984) Increase of corticotropinreleasing factor staining in rat paraventricular nucleus neurones by depletion of hypothalamic adrenaline. Nature 310: 140–141PubMedCrossRefGoogle Scholar
  58. Morley JE (1981) Neuroendocrine control of thyrotropin secretion. Endocrine Reviews 2: 396–436PubMedCrossRefGoogle Scholar
  59. Nasrallah HA, Coryell WH (1982) Dexamethasone nonsuppression predicts the antidepressant effects of sleep deprivation. Psychiat Res 6: 61 – 64CrossRefGoogle Scholar
  60. Peselow ED, Goldring N, Fieve RR, Wright R (1983) The dexamethasone suppression test in depressed outpatients and normal control subjects. Amer J Psychiat 140: 245 – 247PubMedGoogle Scholar
  61. Philipp M, Maier W, Holsboer F (to be published) Psychopathological correlates of plasma Cortisol after dexamethasone suppression: a polydiagnostic approach. PsychoneuroendocrinolGoogle Scholar
  62. Re RE, Kourides IA, Ridway EC, Weintraub BD, Maloof F (1976) The effect of glucocorticoid administration on human pituitary secretion of thyrotropin and prolactin. J Clin Endocrinol Metab 43: 338–346PubMedCrossRefGoogle Scholar
  63. Rubin RT, Poland RE, Blodgett ALN, Winston RA, Forster B, Carroll BJ (1980) Cortisol dynamics and dexamethasone pharmacokinetics in primary endogenous depression: preliminary findings. Progr in Psychoneuroendocrinol: 223 – 234Google Scholar
  64. Rush J, Giles DE, Roffwarg HP, Parker CR (1982) Sleep EEG and dexamethasone suppression test findings in outpatients with unipolar major depressive illness. Biol Psychiat 17: 327 – 341PubMedGoogle Scholar
  65. Sachar EJ (1975) Neuroendocrine abnormalities in depressive illness. In: Sachar EJ (ed) Topics in psychoneuroendocrinology. Grune & Stratton, New York San Francisco London, p 135–156Google Scholar
  66. Sachar, EJ, (1978) Neuroendocrine responses to psychotropic drugs. In: Lipton MA, DiMascio A, Killam KF (eds) Psychopharmacology: a generation of progress. Raven Press, New York, p 499–507Google Scholar
  67. Stokes PE, Stoll PM, Koslow SH, Maas JW, Davis JM, Swann AC, Robins E (1984) Pretreatment DSt and hypothalamic-pituitary-adrenocortical function in depressed patients and comparison groups. Arch Gen Psychiat 41: 257 – 267PubMedCrossRefGoogle Scholar
  68. Sutton RE, Koob GF, Le Moal M, Rivier J, Vale W (1982) Corticotropin releasing factor produces behavioral activation in rats. Nature 297: 331 – 333PubMedCrossRefGoogle Scholar
  69. Swanson LW, Sawchenko PE, Rivier J, Vale W (1983) Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: an immunohistochemical study. Neuroendocrinol 36: 165 – 186CrossRefGoogle Scholar
  70. Thomas EB, Levine S, Arnold WJ (1968) Effects of maternal deprivation and incubations rearing upon adrenocortical activity in the adult rat. Develop Psychobiol 1: 21–23CrossRefGoogle Scholar
  71. Trachsler E, Höchli D, Luckner N v, Woggon B (1985) Dexamethasone suppression test before and after partial sleep deprivation in depressed schizophenic and schizoaffective patients. Pharmacopsychiat 18: 110–111CrossRefGoogle Scholar
  72. Valentino RJ, Foote SL, Aston-Jones G (1983) Corticotropin-releasing factor activates noradrenergic neurons of the locus coeruleus. Brain Res 270: 363 – 367PubMedCrossRefGoogle Scholar
  73. Waldmeier PC, Baumann PA, Hauser K, Maitre L, Storni A (1982) Oxaprotiline, a noradrenaline uptake inhibitor with an active and an inactive enantiomer. Biochem Pharmacol 31:2169–2176PubMedCrossRefGoogle Scholar
  74. Wilens TE, Ritchie JC, Carroll BJ (1984) Comparison of plasma Cortisol and corticosterone in the dexamethasone suppression test for melancholia. Psychoneuroendocrinol 9: 45 – 55CrossRefGoogle Scholar
  75. Winokur A, Caroff SN, Amsterdam JD, Maislin G (1984) Administration of thyrotropin-releasing hormone at weekly intervals results in a diminished thyrotropin response. Biol Psychiat 5: 695–702Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1986

Authors and Affiliations

  • F. Holsboer

There are no affiliations available

Personalised recommendations